While availability of biopsy samples might be a limiting factor for some cancers, the observation that serum anti-AEG-1 antibody might serve as a biomarker for aggressive cancers is encouraging and needs to be validated in multiple cohorts in independent centers. This evidence concerns the gene MTDH and cancer.